ACHV NASDAQ
Achieve Life Sciences, Inc.
1W: -1.1%
1M: -13.3%
3M: +5.8%
YTD: +31.6%
1Y: +32.9%
3Y: +79.2%
5Y: -17.1%
$6.89
+0.35 (+5.35%)
Weekly Expected Move ±7.7%
$5
$6
$6
$7
$7
Credit Risk of going bust: higher than 53% of companies Debt: 2.2% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.04 (down 99.5%), Achieve Life Sciences, Inc. would be worth roughly what it owes.
Total debt $14.9M against a stock market value of $673.0M.
Distance to default 4.85 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $11.2M (short-term plus half of long-term), stock volatility 80.5%; Altman Z'' -10.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.04 (down 99.5%), Achieve Life Sciences, Inc. would be worth roughly what it owes.
Total debt $14.9M against a stock market value of $673.0M.
Distance to default 4.85 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $11.2M (short-term plus half of long-term), stock volatility 80.5%; Altman Z'' -10.30. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$673.0M
52W Range2.62-8.64
Volume701,504
Avg Volume1,736,261
Beta2.31
Dividend—
Analyst Ratings
Company Info
CEOAndrew D. Goldberg
Employees28
SectorHealthcare
IndustryBiotechnology
IPO Date1995-10-12
Websiteachievelifesciences.com
22722 29th Dr. SE
Bothell, WA 98021
US
Bothell, WA 98021
US
14256861500
About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Latest News
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Stock Has Average Target Price of $15.50
Achieve Life Sciences (NASDAQ:ACHV) Share Price Breaks Above 200-Day Moving Average – Time to Sell?
Achieve Life Sciences (NASDAQ:ACHV) Shares Gap Up – Here’s What Happened
Achieve Life Sciences appoints Benjamin Halladay as CFO
Achieve a new Buy at Stifel on potential of smoking cessation drug cytisinicline
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Halladay Benjamin | A-Award | 200,000 | $7.01 | 2026-10-05 |
| Halladay Benjamin | A-Award | 200,000 | — | 2026-10-05 |
| Halladay Benjamin | 0 | — | 2026-10-05 | |
| Stewart Richard Alis | S-Sale | 20,626 | $8.49 | 2026-08-19 |
| Sellig Thomas | A-Award | 25,000 | $6.18 | 2026-07-27 |